Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2003-01-17
2009-12-29
Kelly, Robert M (Department: 1633)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C424S093100, C424S093210, C514S04400A, C435S006120, C435S252100, C435S471000
Reexamination Certificate
active
07638334
ABSTRACT:
Inhibitors of mismatch repair can be used to generate hypermutable cells and organisms. By inhibiting this process in cells, new cell lines and varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of homologous recombination. These methods are useful for generating targeted loci that can alter the expression profiles of target genes as well as tag exons of a gene with a reporter marker to facilitate the monitoring of a given gene product when the host is grown under different conditions or exposed to biological and chemical entities.
REFERENCES:
patent: 5272071 (1993-12-01), Chappel
patent: 5681744 (1997-10-01), Greenstein
patent: 5922601 (1999-07-01), Baetscher et al.
patent: 5965415 (1999-10-01), Radman et al.
patent: 6146894 (2000-11-01), Nicolaides et al.
patent: 6166178 (2000-12-01), Chech et al.
patent: 6355412 (2002-03-01), Stewart et al.
patent: 6596541 (2003-07-01), Murphy et al.
patent: 6921666 (2005-07-01), Nicolaides et al.
patent: 7026119 (2006-04-01), Nicolaides et al.
patent: 2002/0151059 (2002-10-01), Te Riele et al.
patent: WO 97/05268 (1997-02-01), None
patent: WO 99/29837 (1999-06-01), None
patent: WO 01/59092 (2001-08-01), None
patent: WO 01/61012 (2001-08-01), None
patent: WO 01/68882 (2001-09-01), None
patent: WO 02/054856 (2002-07-01), None
patent: WO 03/072732 (2003-09-01), None
Deonarain (1998) Exp. Opin. Ther. Pat., 8(1): 53-69.
Gorecki (2001) Exp. Opin. Emerging Drugs, 6(2): 187-98.
Verma, et al. (1997) Nature, 389: 239-42.
Eck, et al. (1996) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., McGraw-Hill, New York, NY., pp. 77-101.
Stryer (1988) Biochemistry, 3rdEd., WH Freeman & Co., New York, NY, pp. 77 and 82.
mARTI, et al. (2002) J. Cell. Physiol., 191: 28-41.
Flores-Rozas, et al. (2000) TIBS, 196-200.
Henke, et al. (2002) Appl. Microbiol. Biotechnol., 60: 320-26.
Warlick, et al. (2000) Biochem. Pharmacol., 59: 141-51.
Allen, D.J., et al., “MutS mediates heteroduplex loop formation by a translocation mechanism,”EMBO J., 1997, 16(4), 4467-4476.
Baker, S.M., et al., “Male defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis,”Cell, Jul. 28, 1995, 82, 309-319.
Belmont, P., et al., “Synthesis and study of a new adenine—acridine tandem, inhibitor of exonuclease III,”Bioorg. Med. Chem. Lett., 2000, 10, 293-295.
Bhaumik, S., et al., “Optical imaging ofRenillaluciferase reporter gene expression in living mice,”Proc. Natl. Acad. Sci.USA, Jan. 8, 2002, 99(1), 377-382.
Bjornson, K.P., et al., “Modulation of MutS ATP hydrolysis by DNA cofactors,”Biochem., 2000, 39, 3176-3183.
Brasier, A.R., et al., “Optimized use of the firefly luciferase assay as a reporter gene in mammalian cell lines,”BioTechniques, 1989, 7(10),1116-1122.
Chino, M., et al., “Effect of a novel antibiotic, heliquinomycin, on DNA helicase and cell growth,”J. of Antibiot., May 1998, 51(5), 480-486.
Colcher, D., et al., “Use of monoclonal antibodies as radiopharmaceuticals for the localization of human carcinoma xenografts in athymic mice,”Meth. Enzymol., 1986, 121, 802-816.
De Wind, N., et al., “Inactivation of the mouseMsh2gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer,”Cell, Jul. 28, 1995, 82, 321-300.
Elliott, B., et al., “Repair of double-strand breaks by homologous recombination in Mismatch Repair-defective mammalian cells,”Mol. Cell Biol., Apr. 2001, 21(8), 2671-2682.
Galio, L., et al., “ATP hydrolysis-dependent formation of a dynamic ternary nucleoprotein complex withMutSandMutL,”Nucl. Acids-Res., 1999, 27(11), 2325-2331.
Grasso, L., et al., “Molecular analysis of human interleukin-9 receptor transcripts in peripheral blood mononuclear cells. Identification of a splice variant encoding for a nonfunctional cell surface receptor,”J. Biol. Chem., Sep. 11, 1998, 273(37), 24016-24024.
Guarente, L., et al., “Fusion ofEscherichia colilacZ to the cytochrome c gene ofSaccharomyces cerevisiae,” Proc. Natl. Acad. Sci.USA, Apr. 1981, 78(4), 2199-2203.
Huang, Y-C., et al., “N-ethylmaleimide profiling of yeast NADP-dependent isocitrate dehydrogenase,”Arch. Biochem. Biophys., Jan. 10, 1995, 316(1), 485-492.
Igoucheva, O., et al., “Targeted gene correction by small single-stranded oligonucleotides in mammalian cells,”Gene Ther., 2001, 8, 391-399.
Inbar, O., et al., “The relationship between homology length and crossing over during the repair of a broken chromosome,”J. Biol. Chem., Oct. 6, 2000, 275(40), 30833-30838.
Jiricny, J., et al., “Mismatch repair defects in cancer,”Curr. Opon. Genet. Dev., 2000, 10, 157-161.
Kaufman, R.J., et al., “Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus,”Nucl. Acids Res., 1991, 19(16), 4485-4490.
Kukhanova, M., et al., “Unique inhibitory effect of 1-(2′-deoxy-2′fluoro-β-L-arabinofuranosyl)-5-methyluracil 5′-triphosphate on Epstein-barr virus and human DNA polymerases,”Biochem. Pharmacol., 1998, 55, 1181-1187.
Kuwakado, K., et al., “Aphidicolin potentiates apoptosis induced by arabinosyl nucleosides in human myeloid leukemia cell lines,”Biochem. Pharmacol., 1993, 46(11), 1909-1916.
Lehninger, A.L., The amino acid building blocks of proteins,Biochemistry, 2ndEd. Worth Publishers, Inc., 1975,Chapter 4, 72-77.
Lemaigre, F.P., et al., “Transcriptional control of genes that regulate glycolysis and gluconeogenesis in adult liver,”Biochem. J., 1994, 303, 1-14.
Lin, C.T., et al., “Suppression of gene amplification and chromosomal DNA integration by the DNA mismatch repair system,”Nucl. Acid Res., 2001, 29(16), 3304-3310.
Lipkin, S.M., et al., “MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability,”Nat. Genet., Jan. 2000, 24, XP-002165243, 27-35.
Liu, T., et al., “Microsatellite instability as a predictor of a mutation in a DNA mismatch repair gene in familial colorectal cancer,”Genes Chrom. Cancer, 2000, 27, 17-25.
Loeken, M.R., “Effects of mutation of the CREB binding site of the somatostatin promoter on cyclic AMP responsiveness in CV-1 cells,”Gene Expr., 1993, 3(3), 253-264.
Ma, C., et al., “Sister chromatid fusion initiates amplification of the dihydrofolate reductase gene in Chinese hamster cells,”Genes Dev., 1993, 7, 605-620.
Martin, S.J., et al., “Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis,”J. Immunol., Sep. 15, 1990, 145(6), 18591867.
McGehee, R.E., et al., “Differentiation-specific element: acis-acting developmental switch required for the sustained transcriptional expression of the angiotensinogen gene during hormonal-induced differentiation of 3T3-L1 fibroblasts to adipocytes,”Mol. Endocrinol., 1993, 7, 551-560.
Mellon, P.L., et al., “Regulation of transcription by cyclic AMP-dependent protein kinase,”Proc. Natl. Acad. Sci.USA, Jul. 1989, 86, 4887-4891.
Modrich, P., “Mismatch repair, genetic stability, and cancer,”Science, Dec. 23, 1994, 266, 1959-1960.
Nicolaides, N.C., et al., “A naturally occurringhPMS2mutation can confer a dominant negative mutator phenotype,”Mol. Cell. Biol., Mar. 1998, 18(3), 1635-1641.
Nicolaides, N.C., et al., “Genomic organization of the humanPMS2gene family,”Genomics, 1995, 30, 195-206.
Nicolaides, N.C., et al., “Interleukin 9: a candidate gene for asthma,”Proc. Natl. Acad. Sci. USA, Nov. 1997, 94, 13175-13180.
O'Reilly, M.A., et al., “Identification of an activating transcription factor (ATF) binding site in the human transforming growth factor-β2 promote
Grasso Luigi
Kline J. Bradford
Nicolaides Nicholas C.
Sass Philip M.
Kelly Robert M
Morphotek Inc.
Woodcock & Washburn LLP
LandOfFree
Method for generating engineered cells by homologously... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for generating engineered cells by homologously..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for generating engineered cells by homologously... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4094792